peginesatide

Trade name: Omontys

Peptideapproved

Approved

Mar 27, 2012

Peginesatide, developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. — Wikipedia

Clinical trial activity

19 trials · 3 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2004 (NCT00097747)

2000s

2010s

Approved for

Studied for

Oral

Parenteral

Yes

Topical

Black box warningFirst in class

NCT ID	Phase	Start date	Sponsor(s)
NCT01737879	Phase 4	Oct 1, 2012	Amgen
NCT01478971	Phase 3	Oct 1, 2011	Affymax, Takeda
NCT00752791	Phase 2	Oct 1, 2008	Affymax, Takeda
NCT00752609	Phase 2	Sep 1, 2008	Affymax, Takeda
NCT00680043	Phase 2	Jun 1, 2008	Affymax, Takeda
NCT00629876	Phase 1	Jan 1, 2008	Affymax, Takeda
NCT00598442	Phase 3	Nov 1, 2007	Affymax, Takeda
NCT00597584	Phase 3	Oct 1, 2007	Affymax, Takeda
NCT00598273	Phase 3	Oct 1, 2007	Affymax, Takeda
NCT00597753	Phase 3	Sep 1, 2007	Affymax, Takeda
NCT00434330	Phase 2	Dec 1, 2006	Affymax
NCT00453973	Phase 2	Nov 1, 2006	Affymax
NCT00372489	Phase 2	Sep 1, 2006	Affymax
NCT00314795	Phase 2	Apr 1, 2006	Takeda
NCT00272662	Phase 2	Jan 1, 2006	Affymax
NCT00228436	Phase 2	Sep 1, 2005	Affymax
NCT00228449	Phase 2	Jul 1, 2005	Affymax
NCT00109291	Phase 2	Mar 1, 2005	Affymax
NCT00097747	Phase 1	Aug 1, 2004	Affymax

Showing 19 of 19 trials

Page 1 / 1

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Affymax	For profit	17	13	3	2004
Takeda	For profit	10	5	3	2006
Amgen	For profit	1	1	1	2012

3 organizations

Page 1 / 1

Organization	Org type	Relationship	Date
Affymax	For profit	NDA	Mar 27, 2012
Takeda	For profit	MKTG	Mar 27, 2012
Takeda	For profit	NDA2	Mar 27, 2012